Cumulative survival time indicated that the prognosis of ccRCC patients with high level of CD8+ T lymphocytes were better than ccRCC patients with low level of CD8+ T lymphocytes (p = 0.0300) (Figure 1F). The gene discussed is CD8A; the disease is nonpapillary renal cell carcinoma.